Promedior Announces Presentation Of Interim Phase 2 Data On PRM-151 In Myelofibrosis At The Upcoming Congress Of European Hematology Association
6/5/2014 7:41:29 AM
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company’s ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by